Prognostic Value of Right Ventricular Afterload in Patients Undergoing Mitral Transcatheter Edge-to-Edge Repair

• Published in: Journal of the American Heart Association Vol. 13; no. 8; p. e033510
• Main Authors: Bou Chaaya, Rody G, Hatab, Taha, Samimi, Sahar, Qamar, Fatima, Kharsa, Chloe, Aoun, Joe, Faza, Nadeen, Little, Stephen H, Atkins, Marvin D, Reardon, Michael J, Kleiman, Neal S, Nagueh, Sherif F, Zoghbi, William A, Guha, Ashrith, Zaid, Syed, Goel, Sachin S
• Format: Journal Article
• Language: English
• Published: England John Wiley and Sons Inc 16.04.2024; Wiley
• Subjects: mitral regurgitation; mitral transcatheter edge‐to‐edge repair; Original Research; pulmonary effective arterial elastance; pulmonary hypertension; right ventricular afterload; mitral transcatheter edge‐to‐edge repair; pulmonary effective arterial elastance; right ventricular afterload; mitral regurgitation; pulmonary hypertension
• ISSN: 2047-9980; 2047-9980
• DOI: 10.1161/JAHA.123.033510

Pulmonary hypertension (PH) and secondary mitral regurgitation (MR) are associated with adverse outcomes after mitral transcatheter edge-to-edge repair. We aim to study the prognostic value of invasively measured right ventricular afterload in patients undergoing mitral transcatheter edge-to-edge repair. We identified patients who underwent right heart catheterization ≤1 month before transcatheter edge-to-edge repair. The end points were all-cause mortality and a composite of mortality and heart failure hospitalization at 2 years. Using the receiver operating characteristic curve-derived threshold of 0.6 for pulmonary effective arterial elastance ([Ea], pulmonary artery systolic pressure/stroke volume), patients were stratified into 3 profiles based on PH severity (low elastance [HE]: Ea <0.6/mean pulmonary artery pressure (mPAP)) <35; High Elastance with No/Mild PH (HE-): Ea ≥0.6/mPAP <35; and HE with Moderate/Severe PH (HE+): Ea ≥0.6/mPAP ≥35) and MR pathogenesis (Primary MR [PMR])/low elastance, PMR/HE, and secondary MR). The association between this classification and clinical outcomes was examined using Cox regression. Among 114 patients included, 50.9% had PMR. Mean±SD age was 74.7±10.6 years. Patients with Ea ≥0.6 were more likely to have diabetes, atrial fibrillation, New York Heart Association III/IV status, and secondary MR (all <0.05). Overall, 2-year cumulative survival was 71.1% and was lower in patients with secondary MR and mPAP ≥35. Compared with patients with low elastance, cumulative 2-year event-free survival was significantly lower in HE- and HE+ patients (85.5% versus 50.4% versus 41.0%, respectively, =0.001). Also, cumulative 2-year event-free survival was significantly higher in patients with PMR/low elastance when compared with PMR/HE and patients with secondary mitral regurgitation (85.5% versus 55.5% versus 46.1%, respectively, =0.005). Assessment of the preprocedural cardiopulmonary profile based on mPAP, MR pathogenesis, and Ea guides patient selection by identifying hemodynamic features that indicate likely benefit from mitral-transcatheter edge-to-edge repair in PH or lack thereof.